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Replication-defective mutants of herpes simplex virus 1 (HSV-1) elicit immune responses in mice that reduce acute and
latent infection after corneal challenge and are protective against development of disease. To understand the basis for the
protective immunity induced by this new form of immunization, we investigated the contribution of various components of the
immune response to protection against corneal infection and disease. Passive transfer of sera from mice immunized with the
replication-defective mutant virus, d301, its parental HSV-1 strain, or uninfected cell lysate was used to examine the role of
antibody. Despite posttransfer neutralizing antibody titers equivalent to those in control mice directly immunized with mutant
virus, recipients of immune serum showed no reductions in primary replication in the eye, keratitis, or latent infection of the
nervous system. However, immune serum protected mice from encephalitis and death. To examine the contribution of T cell
subsets to protection, mice were immunized once with mutant virus and then were depleted in vivo of CD41 or CD81 T cells
prior to corneal challenge. CD4 depletion resulted in higher titers of challenge virus in the eye at 3 to 4 days after challenge
compared to control mice. Latent infection of the nervous system was increased by depletion of CD41 T cells but not by
depletion of CD81 T cells. Keratitis developed only in a portion of the CD81 T cell-depleted mice, suggesting that an
immunopathologic potential of CD41 T cells is held in check when immune CD81 T cells are also present. Taken together,
these data support a role for antibody induced by immunization with a replication-defective virus principally in protecting the
central nervous system from disease, roles for CD41 T cells in reducing primary replication in the eye and protecting against
latent infection of the nervous system, and a role for CD81 T cells in regulating the immunopathologic activity of CD41 T cells.
© 1997 Academic Press
INTRODUCTION
Herpes simplex virus is the etiologic agent of a variety
of significant human diseases. Herpes simplex virus 1
(HSV-1) causes common cold sores but also is respon-
sible for most cases of viral encephalitis. Herpes kerati-
tis, in which progressive scarring of the cornea occurs in
response to HSV infection and reactivation, is the second
most common cause of nontraumatic corneal blindness
(49). HSV-1 infections initiate at a mucosal surface where
primary replication can lead to lesion formation. The
virus also can establish acute and latent infections in
sensory neurons innervating the primary site of infection
and spread from there to the central nervous system.
Thus, there are several stages at which a preexisting,
protective immune response could intervene in HSV in-
fection, each potentially different with regard to anatom-
ical restrictions and relevant immune effector mecha-
nisms. Determination of these sites of intervention and
the immune components that provide protection at each
site is crucial to development of a safe and effective
vaccine to prevent HSV infection and disease.
Numerous approaches to vaccination against HSV
have been developed, including inactivated and glyco-
protein subunit vaccines and live attenuated virus or viral
vectors (8). A recent approach that combines the safety
of an inactivated vaccine with the broad spectrum immu-
nogenicity of live virus utilizes genetically engineered
mutants of HSV that are live but impaired for replication,
the so-called single cycle and replication-defective vi-
ruses. These replication-impaired mutants of HSV have
been used to elicit immune responses in mice (13, 33, 34,
39) and guinea pigs (10, 29, 30) that are protective
against HSV-1 and HSV-2 challenge, respectively. Vi-
ruses that contain a deletion in the UL29 (ICP8) gene
express a, b, and g1 gene products in infected cells but
cannot replicate their DNA (15). Therefore, no progeny
virions are produced to spread further within the host.
We have demonstrated that immunization of mice with
the ICP82 replication-defective virus, d301, can reduce
infection and prevent disease after corneal challenge
with virulent HSV-1 (33). Specifically, the immune re-
sponse elicited by immunization reduces primary repli-
cation of challenge virus in the eye tissue and virus
shedding from the corneal epithelium. Acute infection by
challenge virus of the trigeminal ganglia (TG), which
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contain neurons innervating the cornea, is undetectable
in immunized mice. Furthermore, latent infection of the
TG by challenge virus is dramatically reduced, as dem-
onstrated by explant reactivation (33) and by in situ
hybridization of TG sections with a probe for latency
associated transcripts (LAT) (34). After challenge, no
signs of keratitis or encephalitis develop in d301-immu-
nized mice but are rampant in control mice immunized
with uninfected cell lysate (33, 34). Thus, protective ef-
fects have been identified at several stages in the patho-
genesis of challenge virus infection and disease induc-
tion in mice immunized with replication-defective virus.
A variety of humoral and cellular effector mechanisms
potentially could be responsible for the protective effects
seen at each stage. We have demonstrated that subcu-
taneous immunization with d301 elicits HSV-specific
neutralizing antibody and splenic T cell proliferative re-
sponses (33). These responses and most of their protec-
tive effects are maintained for at least 7 months after
immunization (34). The IgG2a:IgG1 ratio of HSV-specific
antibody indicates a Th1-type response is elicited by
replication-defective virus (7), a conclusion which is sup-
ported by observation of an inhibitory effect of in vivo
treatment with anti-IFNg antibody on induction of the
IgG2a response (38). Immunization with ICP82 replica-
tion-defective virus also elicits CD81 cytolytic T cell re-
sponses to HSV-infected cells (6). However, nothing is
known about which components of the immune re-
sponse elicited by these mutant viruses effect the dra-
matic protection seen against corneal challenge of mice
with HSV-1. This information is essential to understand-
ing the nature of protective, and protective versus patho-
logic, immune responses against HSV and may, in turn,
further the development of safe and effective vaccines to
prevent HSV infection. Here we define the contribution of
replication-defective virus-immune serum antibody and T
cell subsets to protection at several stages in the patho-
genesis of HSV-1-mediated corneal infection and dis-
ease through a combination of serum passive transfer
and in vivo depletion of CD41 and CD81 T cell subsets.
MATERIALS AND METHODS
Cells and viruses
The wild-type (wt) KOS1.1 (21) and mP (18) strains of
HSV-1 were grown on Vero cell monolayers. The d301
strain is a replication-defective mutant of KOS1.1 bearing
a deletion in the UL29 gene encoding ICP8 (14). This
virus expresses products of the a, b, and g1 gene
classes in infected normal cells but propagation requires
a cell line, S-2, that is stably transformed with the UL29
gene. Cell lysate stocks of all viruses were prepared as
previously described (34). The particle to plaque forming
unit (PFU) ratio of mutant and wt virus preparations
appears to be similar because cells in culture exposed to
a given number of PFU of mutant virus contain equal
levels of viral DNA compared with cells exposed to the
same number of PFU of wt virus (15). A portion of the wt
virus stock was inactivated by exposure to UV light as
previously described (33).
Animals and inoculations
Female BALB/c mice, 6 weeks of age, were purchased
from the National Cancer Institute (Fredericksburg, MD)
or Taconic (Germantown, NY) and were acclimated 1
week before use. The mice were housed in accordance
with institutional policies and National Institutes of
Health guidelines (1). For immunization, hair on the left
rear flank of each mouse was trimmed and 2 3 106 PFU
of d301, KOS1.1, or equivalent amounts of UV-inactivated
KOS1.1 or control cell lysate were inoculated by subcu-
taneous (s.c.) injection of a 20-ml vol using a 26-g needle.
Corneal challenge with the mP strain of HSV-1 was
carried out by inoculation of 2 3 105 PFU/eye of virus
onto the scarified cornea as described previously (33).
Antibody and immune serum production
Rat hybridomas GK1.5 (ATCC TIB 207), specific for
CD4, and 53-6.72 (ATCC TIB 105), specific for CD8, were
expanded in vitro in DME plus 15% or RPMI plus 10%
FCS, respectively, and transferred to McCoy’s 5A me-
dium (Gibco) plus 8% FCS. Antibody from supernatants
was purified over a column of Sepharose 4B–protein G
(Sigma). Protein-containing fractions were pooled, con-
centrated using microconcentrators (Amicon), and dia-
lyzed at 4°C against PBS. Antibody concentration was
adjusted to 1 mg/ml or 2 mg/ml with sterile PBS based on
OD280 spectrophotometric determination, and stored at
280°C.
Immune serum for passive transfer was generated
by thrice immunizing groups of 9–11 mice s.c. in the
flank at 1-month intervals with 2 3 106 PFU of KOS1.1
wt virus, the d301 mutant virus, UV-inactivated KOS1.1
(1 3 108 PFU/ml prior to inactivation), or an equivalent
amount of control lysate. Blood was collected from the
tail veins at 8, 10, and 13 days after the final immuni-
zation, and serum was harvested as described previ-
ously (33). All samples within each group were pooled,
passed through a 0.22-mm filter (Gelman Science), and
stored briefly at 4°C.
Passive transfer of immune serum
Groups of 6–8 female BALB/c mice, 6 weeks of age,
were inoculated intraperitoneally (i.p.) with 0.3 ml hyper-
immune serum 4 h prior to challenge and again 3 days
after challenge. At 6 h after serum transfer, sera were
collected from a cohort of recipient animals for determi-
nation of posttransfer serum neutralizing antibody titers.
Sera were also collected from a cohort of control mice
that had been directly immunized 1 month previously
with the d301 virus.
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T cell depletions
Groups of five mice immunized with d301 virus 1
month previously were injected i.p. with 0.3 ml of mono-
clonal antibodies GK1.5 or 53-6.72 at 1 mg/ml or a mix-
ture of the antibodies at 2 mg/ml each in a total volume
of 0.3 ml, on days 23, 21, 13, 17, 111, and 114 with
respect to challenge. As controls, additional groups of
immunized mice were injected with 0.3 ml of isotype-
matched normal rat IgG (1 mg/ml; Caltag) or PBS. Mice
immunized with control lysate were injected with PBS.
Determination of neutralizing antibody titers
In T cell depletion studies, sera were collected prior to
and 3, 6, or 9 days after challenge of a cohort of immu-
nized mice treated with anti-CD4, anti-CD8, or control
IgG. The titers of HSV-specific neutralizing antibody in all
sera were determined by using a CPE inhibition assay as
previously described (34), except that mixtures without
complement were incubated for 60 min and those with
complement were incubated for 100 min.
FACS Analysis
Splenocytes from two mice treated on days 23 and
21 with anti-CD4 or anti-CD8 antibody and from two
age-matched, untreated mice were collected and pooled.
The mononuclear cell fraction was isolated by centrifu-
gation over liquid separation medium (Organon Tech-
nika), washed, and resuspended at 2 3 107/ml in FACS
buffer (PBS containing 1% (wt/vol) BSA, fraction V, and
0.1% sodium azide). To aliquots of 106 cells, 1 mg FITC-
conjugated anti-CD8 (CT-CD8a), anti-CD4 (YTS191.1), or
control IgG (all from Caltag), in 10-ml vol, was added and
incubated on ice for 30 min. Cells were washed three
times and resuspended in FACS buffer, and the fluores-
cence intensity was determined by flow cytometric anal-
ysis. The percentage of lymphocytes positive for a given
cell surface marker in depleted mice was compared with
that in untreated mice to determine the efficacy of de-
pletion.
Assays of acute and latent infection
Acute replication at various times after corneal chal-
lenge was assessed by viral titer in eye swabs as de-
scribed previously (34). Viral titers were determined by
standard plaque assay (22).
To assay for reactivating virus indicative of latent in-
fection, TG were removed from animals 28 days after
corneal challenge, minced, and placed in culture on Vero
cell monolayers. Cultures showing no CPE after 10 days
of incubation were collected, sonicated (Heat Systems),
and placed onto fresh Vero cell monolayers to look for
plaque formation.
Keratitis and encephalitis evaluation
Mice were observed daily in the period postchallenge
for clinical signs of encephalitis: ruffled fur, hunched
posture, ataxia, and anorexia. Keratitis scores, repre-
senting both severity and extent of disease, were deter-
mined for each eye of challenged mice as described
previously (33).
Histology
Twenty eight days after challenge, T cell-depleted
mice and control IgG-treated mice were sacrificed. Eyes
were dissected, fixed in formalin for 1 day, and trans-
ferred to 70% ethanol. Sections were obtained from par-
affin-embedded tissue and stained with hematoxylin and
eosin.
Statistical analyses
Fisher’s exact test was used to determine the signifi-
cance of differences in (1) the proportion of latently
infected trigeminal ganglia between immunized mice de-
pleted of CD41 or CD81 T cells and those treated with
control IgG, and (2) the proportion of d301 serum recip-
ients succumbing to challenge virus infection compared
with wt and control serum recipients. The unpaired stu-
dent’s t test was used to compare geometric mean viral
titers between groups on individual days, with no correc-
tion for multiple comparisons.
RESULTS
To investigate the role of various effector mechanisms
in providing the protective immunity elicited by replica-
tion-defective mutant virus, we have chosen to allow the
immune response to mutant virus to develop normally in
immunized mice before we isolated or deleted a compo-
nent of that response.
Serum passive transfer
In this study, we evaluated the role of serum antibody
by passive transfer of immune serum to naive animals
prior to challenge. An alternative approach, that of de-
pleting mice of B cells prior to immunization by in vivo
administration of anti-m antibody, was not feasible be-
cause virus-specific T cell responses have been shown
to develop abnormally under these conditions (44). Prior
to passive transfer, sera collected from mice immunized
thrice with mutant, wt, or UV-inactivated virus had neu-
tralizing titers equal to or greater than the titer of sera
from control mice immunized once with mutant virus
(preinjection, Table 1). At 6 h after serum transfer, titers of
neutralizing antibody recovered from d301 mutant or wt
serum recipients were essentially equivalent to the titer
in control animals directly immunized with mutant virus
(d301 virus-immunized, Table 1), indicating that serum
neutralizing activity had been reconstituted to roughly
317PROTECTIVE ROLE OF HSV-SPECIFIC ANTIBODY AND T CELLS
physiologic levels at the time of challenge. Neutralizing
activity recovered from the serum of mice injected with
inactivated virus serum was lower than that of directly
immunized animals. Passive transfer of immune serum
was repeated 3 days after challenge to maintain serum
antibody levels for at least 1 week postchallenge (20).
Effect of serum antibody on primary replication of chal-
lenge virus. Titers of virus shed in the tear film on days 1
through 5 after challenge were equivalent in all adop-
tively transferred mice, regardless of the serum source
(Fig. 1). The titers of virus from mice directly immunized
with mutant virus were significantly lower than in the
serum recipients at all time points (P , 0.025 on day 1),
reaching undetectable levels by 5 days after challenge
(Fig. 1). Thus, serum antibody at a titer equivalent to that
in mice immunized once with mutant virus appeared to
play little or no role in reducing replication of virus at the
primary site of infection.
Effect of serum antibody on development of disease
following challenge infection. In mice receiving wt virus
serum, we observed no signs of disease after challenge
virus infection. In mice receiving d301 serum, 6/8 mice
showed ruffled fur by 5–7 days after challenge and 2/8
developed more distinct and protracted ruffling and also
lost weight (data not shown). All mice in the groups
receiving UV-wt serum or CL serum showed distinctly
ruffled fur and were anorexic following challenge. Sever-
ity of symptoms correlated with eventual mortality; thus,
all but one of the mice receiving CL or UV-wt serum
succumbed to encephalitis (not significantly different;
P 5 0.40), whereas only 2 of the mice receiving d301
serum and none of those receiving wt serum died (not
significantly different; P 5 0.26; Fig. 2). This result indi-
cates that passively transferred serum antibody, gener-
ated in mice immunized with the mutant virus and
present in the serum at a level equivalent to a single
immunization, had the capacity to protect most mice from
development of fatal encephalitis but was not quite as
effective as wt serum.
Mice directly immunized with mutant virus were pro-
tected from developing stromal keratitis following cor-
neal challenge (Fig. 3). In contrast, transfer of d301 or wt
serum did not protect recipients from developing kerati-
tis (Fig. 3), indicating that HSV-specific serum antibody
does not intervene in development of eye disease, at
least with the amount transferred. The few mice receiv-
ing UV-wt or CL serum that survived more than 7 days
after challenge also developed keratitis.
TABLE 1
Neutralizing Antibody Titers in Sera prior to and after Transfer
Serum Source
Antibody
titer a
Pre-injectionb d301 1024
WT 1024
UV-WT 205
Cell Lysate ,16
Post-transfer c d301 virus-immunizedd 148
d301 195
WT 144
UV-WT ,16
Cell Lysate ,16
a Complement-dependent titers expressed as the reciprocal of the
serum dilution yielding CPE inhibition in 50% of the wells.
b Pooled serum prior to adoptive transfer.
c Serum collected from recipients 6 h after adoptive transfer.
d Serum from mice directly immunized once with d301 3 weeks
earlier.
FIG. 1. Replication of challenge virus in the eyes of animals receiving
immune or control sera. Groups of 6–9 naive mice received injections
of serum collected from mice immunized with mutant d301 (d301), wt or
UV-inactivated wt virus (UV-WT), or lysate of uninfected cells (CL).
Another group was directly immunized with d301 4 weeks earlier. All
mice were challenged by corneal inoculation of virus. Samples of tear
film were collected daily, and titers of infectious virus were determined
by standard plaque assay. Values represent the geometric mean titer of
5 mice/group 6 SEM from a single experiment.
FIG. 2. Effect of transfer of immune serum on survival of challenged
animals. Groups of 6–9 naive mice received injections of serum from
mice immunized with d301 mutant (d301), wt, or UV-inactivated wt virus,
or with control cell lysate. Survival of the serum recipients was then
monitored over time after corneal challenge and expressed as a per-
centage of the original number of mice per group. Data are from the
same experiment described in the legend to Fig. 1.
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Effect of serum antibody on latent infection. We deter-
mined the incidence of latent infection in the TG of
surviving mice at 4 weeks after challenge. Reactivation
of latent virus was detected in a cocultivation assay in
only 24% of TG from mice immunized once with mutant
virus prior to challenge, but was found in 88 and 100% of
TG from mice receiving d301 or wt serum, respectively
(P , 0.001; Table 2). Both TG from the surviving recipient
of UV-wt serum also contained reactivating virus (Table
2). Thus, serum antibody at the levels tested was not
sufficient to protect against latent infection but did con-
tribute to protection of mice by preventing development
of fatal encephalitis. We do not yet know whether the
relative lack of protective efficacy of serum from UV-
inactivated virus-immunized mice compared to mutant or
wt virus-immune serum is a function of lower initial titer
or of differences in affinity or epitope representation.
T cell depletion
The results of the serum transfer experiment sug-
gested a primary role for T cells in mediating protection
at various stages in the pathogenesis of challenge virus
infection, leading us to investigate the contributions
made by different T cell subsets. Adoptive transfer of T
cells from immunized to naive mice would identify only
the functional potential of a certain number of cells taken
from an accessible lymphoid organ. Alternatively, mice
genetically deficient in CD41 or CD81 T cells do not
generate a normal distribution of remaining effectors
after immunization (28). Thus, to directly assess the con-
tribution of virus-specific T cell subsets as mediators of
protection, we immunized mice with replication-defective
virus and then depleted them of CD41 or CD81 T cells by
in vivo administration of anti-CD4 or -CD8 monoclonal
antibody prior to challenge. Affinity-purified rat antibod-
ies GK1.5 (anti-CD4) or 53-6.72 (anti-CD8) were injected
i.p. into groups of mutant virus-immunized mice twice
prior to corneal challenge, and every fourth day thereaf-
ter. Injection of isotype-matched, normal rat IgG or PBS
into mutant virus-immunized mice served as a control for
depletion, and s.c. inoculation of control lysate and sub-
sequent injection of PBS served as a control for immu-
FIG. 3. Development of keratitis in serum recipients after challenge infection. The eyes of groups of mice receiving immune serum or control serum
or of a group directly immunized with mutant virus were evaluated for signs of keratitis. Bars represent the percentage of eyes showing disease at
the indicated time postchallenge. Disease severity (keratitis score) is indicated by open (21), hatched (31), and filled (41) shading. Number of eyes
of surviving mice on each day postchallenge is indicated above the bar. Data are from the same group of mice described in the legend to Fig. 1.
Asterisk indicates assessment curtailed due to death of most mice in the group.
TABLE 2
Incidence of Latent Infection in Serum Recipients
Group
Fraction (percentage)
of ganglia showing
virus reactivation P value
d301 virus-immunized 4/17 (24%)
d301 serum 14/16 (88%) (P , 0.001)a
WT serum 16/16 (100%) (P , 0.001)
UV-WT serum 2/2 (100%) (P 5 0.088)
a Compared with d301 virus-immunized mice by Fisher’s exact test.
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nization. FACS analysis, using a different set of FITC-
conjugated anti-CD4 and anti-CD8 antibodies, of
splenocytes from cohort animals revealed that on the
day of challenge, mice injected with GK1.5 were 97%
depleted of CD41 T cells and those injected with 53-6.72
were nearly 100% depleted of CD81 T cells (data not
shown), in accord with previous depletion studies using
these antibodies (19, 25, 28, 32, 37). Though not as
profound, depletion was still apparent 14 days after chal-
lenge (data not shown).
Effect of T cell depletion on primary replication in
the eye. During the first 2 days after corneal challenge,
the titers of virus shed into the tear film were similar
whether or not mutant virus-immunized mice were de-
pleted of CD41 and/or CD81 T cells (Fig. 4). By 3 days
after challenge, however, titers of virus in the eyes of
mice treated with control Ig were significantly lower than
those of mice depleted of CD41 T cells (P , 0.004) or
double-depleted (P , 0.016). Four days after challenge,
the differences in titer between control mice and those
depleted of CD41 T cells or double-depleted were 1000-
fold and 300-fold, respectively (P , 0.001 and P , 0.008,
respectively). CD8-depleted mice showed no statistically
significant increase in viral titer in the eye except at 4
days postchallenge in one of two experiments (data not
shown). Thus, CD41 T cells appeared to play the major
role in limiting the replication of challenge virus at the
initial site of infection in the corneal epithelium, but this
effect was not manifest for approximately 2 days.
Development of disease in mice depleted of T cell
subsets. All mice that underwent T cell depletion showed
no clinical signs of ill health during initial depletion or
after challenge. Mice treated with both anti-CD4 and
-CD8 antibodies also remained apparently healthy, cor-
roborating the results of the serum adoptive transfer
study which indicated that serum alone could confer
significant protection against fatal encephalitis. Signs of
encephalitis were observed in all control mice inocu-
lated with uninfected cell lysate and treated with PBS,
and mortality in this group was 80%.
Keratitis developed in all mice inoculated with control
lysate and then challenged, but not in any of the eyes of
mice immunized with mutant virus and treated with PBS
or control IgG (Fig. 5). Depletion of CD41 T cells from
mutant virus-immunized mice did not diminish protection
from disease. In contrast, several eyes from immunized
mice depleted of CD81 T cells did develop focal keratitis
which increased in severity with time (Fig. 5). Two eyes
from mice treated with antibody to both T cell subsets
also developed mild keratitis, but not until nearly 3
weeks after challenge. Histologic examination of the
affected corneas in CD8-depleted mice revealed a heavy
infiltration of mononuclear cells and disruption of corneal
architecture 28 days after challenge (Fig. 6A). In contrast,
corneas from CD4-depleted mice contained few mono-
nuclear cells (Fig. 6B) and were indistinguishable from
corneal sections of immunized mice treated with control
IgG (Fig. 6C). Unimmunized mice that survived challenge
virus infection showed severe keratitis at 28 days
postchallenge (Fig. 6D). These results suggest that the
protection against development of keratitis afforded by
immunization with mutant virus can be abrogated when
only CD41, HSV-immune T cells are present at the time
of challenge. This observation in turn suggests that
CD81 T cells elicited by immunization with mutant virus
may regulate the immunopathologic potential of the
CD41 T cells also elicited by immunization.
Incidence of latent infection in mice depleted of T cell
subsets. The presence of latent virus in TG of surviving
mice was assessed by cocultivation assay 4 weeks after
challenge. All ganglia from cell lysate-inoculated mice
but only half of the ganglia from mutant virus-immunized
mice treated with control IgG produced reactivating virus
(Table 3, experiment 1). In mice that were immunized and
depleted of CD41 T cells, no protection from latent in-
fection was observed because 10/10 ganglia produced
reactivating virus (Table 3, experiment 1). The incidence
of latent infection was also increased in immunized mice
treated with anti-CD8 antibody, but this result was not
statistically significant in two independent experiments
(Table 3, experiments 1 and 2) whose reproducibility was
supported by the observation of virtually identical eye
titers in the two experiments (data not shown). These
results suggest a role for CD41 T cells in reducing the
incidence of latent infection as assessed by reactivation.
Further studies are in progress to corroborate these
observations by quantitation of challenge virus genomes
in latently infected TG.
FIG. 4. Increased replication of challenge virus in the eyes of T
cell-depleted mice. Mutant virus-immunized mice were depleted of T
cell subsets by in vivo administration of monoclonal antibodies directed
to CD4 or CD8. An additional group was depleted of both, and another
group received normal rat IgG as a control. The mice then underwent
corneal challenge and samples of tear film were collected daily. Titer of
infectious virus was assessed by standard plaque assay. Values rep-
resent the geometric mean titer of 5 mice/group 6 SEM from one of two
experiments.
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Postdepletion serum titers of neutralizing antibody. We
evaluated the titers of neutralizing antibody present in
the serum of depleted mice over time after challenge
to seek functional evidence of CD4 depletion and to
determine whether loss of T help could have contrib-
uted to effects seen in CD4-depleted mice. After treat-
ment and challenge, HSV-specific antibody titers rose
in mice depleted of CD81 T cells and in control mice
compared to prechallenge titer. In mice depleted of
CD41 T cells, titers remained unchanged through 6
days after challenge and by 9 days after challenge had
risen less than twofold compared to the titer of 1:93
seen prior to treatment and challenge (Table 4). This
result demonstrates an absence of helper function for
antibody production in CD4-depleted mice. However,
the small difference in antibody titers between CD8-
depleted or control mice and CD4-depleted mice,
taken together with the lack of protective activity of
antibody seen upon passive serum transfer, was not
likely to explain the loss of protection against estab-
lishment of latent infection in CD4-depleted mice.
DISCUSSION
We have studied components of the immune response
elicited by immunization with a replication-defective
HSV-1 mutant to determine the contributions of antibody
and T cells to protection against challenge virus infection
of the cornea. Serum antibody elicited by immunization
with mutant virus principally prevents encephalitic infec-
tion of the CNS. CD41 T cells elicited in mice immunized
with a replication-defective mutant strain of HSV-1 are
required for the reduction of challenge virus infection of
the corneal epithelium and appear to decrease latent
infection in the trigeminal ganglion. CD81 T cells appear
to play a role in preventing keratitis, possibly by regulat-
ing the immunopathologic potential of CD41 T cells.
These studies were performed with normal mice in
which the immune response to the mutant virus was
permitted to develop naturally prior to isolation or re-
moval of one component of it. As such, the immune
response examined may be considered physiologic in
magnitude and composition. The results of the serum
FIG. 5. Development of keratitis in mice depleted of CD81 T cells. The eyes of groups of mice challenged after depletion of CD4 or CD8 T cells
were evaluated for signs of keratitis at the indicated times postchallenge. Bars represent the percentage of mice showing signs of stromal disease,
severity of which (keratitis score) is indicated by open (21), hatched (31), or filled (41) shading. Data are from the same experiment described in
the legend to Fig. 4.
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transfer and T cell depletion studies are internally con-
sistent and demonstrate that each component of the
immune response induced by a live, replication-defective
form of virus makes an important contribution to protec-
tion of the host at defined stages of challenge virus
infection.
Our observation that the role of antibody was un-
equivocably confined to protection of the CNS is consis-
tent with those of previous passive serum transfer and T
cell suppression studies in mice which have shown an
effect of antibody on neuronal spread of HSV (31). How-
ever, they appear to conflict with several studies in which
decreased severity of eye disease was seen after pro-
phylactic treatment of mice with HSV-specific monoclo-
nal antibodies (24, 43, 46). It is possible that the serum
concentration of monoclonal antibody achieved in those
studies was much greater than that of our polyclonal
response, which was equivalent to a single immunization
with mutant virus, and that a higher antibody concen-
tration may be necessary to accomplish protection
against corneal infection and disease. Indeed, injection
of 55 mg of monoclonal antibody against HSV-1 gD de-
creases primary replication in the eye (2), but injection
of lower doses does not (23). HSV-specific neutralizing
antibody has a half-life in serum of approximately 4 days
(20). Thus, the two injections of serum we performed
would be expected to protect mice at least half-maxi-
mally over the period postchallenge in which virus
replication in the eye and spread to the TG occurs (9).
Our results with serum passive transfer support the con-
tention that the amount of antibody generated by a
single immunization with replication-defective virus can
protect mice from CNS disease, but does not exclude an
additional role for T cells in CNS protection. Indeed,
serum recipients were not protected as completely as
mice depleted of either CD41 or CD81 T cells. Whether
the passively transferred serum conferred protection
against encephalitis due to its neutralizing activity is not
known.
Numerous studies implicate CD41 T cells as media-
tors of an immunopathologic reaction to wt HSV infection
(11, 27, 37), or possibly a self-antigen revealed upon
ocular herpetic infection (4), which results in develop-
ment of keratitis in naive mice. In contrast, prior immu-
nization with replication-defective virus protects mice
from developing keratitis upon subsequent corneal chal-
lenge. Interestingly, fractionation of this protective im-
mune response by CD81 T cell depletion revealed a
potential for pathologic infiltration of some of the cor-
neas, possibly mediated by the remaining CD41 T cell
population. One possible interpretation is that CD4-me-
diated pathologic activity is normally regulated by the
presence of immune CD81 T cells, suggesting an inter-
play between HSV-immune CD41 and CD81 T cells
during response to challenge. Regulation of CD41 T cell
activity by CD81 cells has previously been suggested
based on the results of T cell depletion studies in naive
mice responding to primary infection with HSV (37). It is
also possible that at least the more severe keratitis we
observed in a few of the mice may have been mediated
by newly generated CD81 T cells repopulating the ani-
mals as the effects of depletion waned. Regardless of
the mechanism, protection against keratitis seen after
immunization with mutant virus underscores the differ-
ence in response to challenge of a naive mouse and one
immunized with replication-defective virus and suggests
the importance of eliciting a balanced immune response
through immunization that includes induction of CD81 T
cells.
CD41 T cells appear to be involved in decreasing
replication of challenge virus in the cornea. This T cell
subset predominates in corneal infiltrates of mice immu-
nized with HSV-1 strain KOS prior to challenge (16), and
MHC class II has been noted on corneal Langerhans
cells (41) and keratinocytes (12) within 48 h of infection
with HSV, indicating that elements essential to CD4-
mediated activity are present. Notably, the difference
between CD4-depleted and control groups in viral repli-
cation in the eye was not apparent until .2 days after
challenge. This delay probably represents the time re-
quired to activate memory cells and/or to recruit them to
TABLE 4
Neutralizing Antibody Titers in Serum of T Cell-Depleted Mice
Treatment group
Neutralizing antibody titer a at dayb
215 23 13 16 19
Predepletion 53c 93
aCD4 114 112 160
aCD8 192 256 716
Ig control 171 256 512
a Complement-dependent titers in a CPE-inhibition assay.
b Days numbered relative to day of challenge.
c Reciprocal of the dilution yielding CPE inhibition in 50% of the wells.
TABLE 3
Reduction of Latent Infection in T Cell-Depleted Animals
Immunogen Treatment
Fraction of positive gangliaa
Expt. 1 Expt. 2
Cell Lysate PBS 4/4
d301 PBS 6/10
d301 rat IgG 5/10 6/14
d301 aCD8 8/9 (P 5 0.091)b 6/14 (P 5 0.648)b
d301 aCD4 10/10 (P 5 0.016)
d301 aCD4 1 8 8/10 (P 5 0.175)
a Number of trigeminal ganglia positive for reactivating virus per
number tested in a standard cocultivation assay.
b Compared with isotype-matched, normal rat IgG control by Fisher’s
exact test.
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the scene of infection. Adoptively transferred, replication-
defective virus-specific CD41 T cells have also been
shown to decrease primary replication of HSV-1 in the
footpad more than CD81 T cells in a different model of
HSV infection (6).
The observation of an increased incidence of latent
infection of the TG, as assessed by explant reactiva-
tion, in immunized mice depleted of CD41 T cells
concurs with a prior observation that CD4-depleted
mice previously immunized with HSV gD-1 show an
increase in severity of neurologic disease after foot-
pad challenge with HSV-2 (32). Further studies will be
necessary to determine whether CD41 T cells from
replication-defective virus-immunized mice affect es-
tablishment of, or reactivation from, latency by chal-
lenge virus. In this regard, we have observed an 80-
fold decrease in the number of neurons expressing
latency-associated transcripts (LATs) in TG sections
from mice immunized twice with mutant virus before
challenge compared with mice immunized with control
lysate before challenge (34), suggesting that the im-
mune response decreases establishment of latent in-
fection by challenge virus. Depletion of CD41 T cells
from naive mice also leads to increased latent infec-
tion of dorsal root ganglia after cutaneous infection
(35). The fact that primary or recurrent infections with
HSV are more severe and frequent in T cell-sup-
pressed patients and in AIDS patients with specific
deletion of CD41 T cells (2,48) also supports the func-
tional importance of CD41 T cells in controlling HSV
infection and reactivation in humans. Depletion of
CD81 T cells from naive mice has been shown to
result in greater neuronal loss in dorsal root ganglia
acutely infected with HSV (45), but our current study
with immunized mice did not examine acute replica-
tion in the nervous system. CD81 T cells have also
been seen to predominate during latency in the TG of
naive A/J mice having undergone primary infection
with HSV-1 (26). Taken together, our observations and
other reports describe the potential of both T cell
subsets to operate in the nervous system and raise
the intriguing possibility that the subsets may function
differentially depending on neuroanatomic location or
immune status.
The mechanism of T cell action in preventing acute
or latent infection by HSV has not yet been elucidated
but could include direct cytolytic effects and/or cyto-
kine expression. Cytolysis of acutely infected neurons
would be detrimental to the host and is unlikely to
occur because of limited MHC molecule expression,
but cytolysis of infected corneal cells as a means of
controlling virus infection would be another possible
scenario. HSV-specific, MHC class I- and class II-
restricted CTL have both been reported in mice (5, 37,
41) and humans (42, 49, 51). CD41 T cells predominate
in the infiltrate of both cornea and TG of naive BALB/c
mice infected with HSV-1, produce Th1 cytokines (4,
41), and are the cause of immunopathology (38). In
naive A/J mice, increased levels of IFNg in the cornea
(19) and IFNg and TNF in the TG (27) have been
demonstrated coincident with CD81 T cell infiltration.
This cytokine expression accompanies an inflamma-
tory response with immunopathologic consequences
that is paradoxically absent in replication-defective
virus-immunized mice. In immunized mice, T cell-de-
rived cytokines may be elaborated much more rapidly
after onset of infection and may exert direct anti-
viral effects which make neighboring corneal cells
refractory to infection, thereby inhibiting corneal
spread of virus and establishment of latent infection in
TG neurons and ultimately limiting the inflammatory
response. Further work on antiviral mechanisms em-
ployed by protective, replication-defective virus-im-
mune T cells will be necessary to distinguish among
these possibilities. Such information will aid in identi-
fying desirable vaccine-induced immune responses.
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